Clinical Trials Logo
  1. Home
  2. Neoplasms, Prostate
  3. NCT00148928

Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA

Neoplasms, Prostate Clinical Trial

Official title:
A Multicenter, Open-label Phase I/II Trial to Evaluate the Safety and Activity of CPC-P501 Protein Formulated With the Adjuvant AS15 as First-line Treatment in Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA

Clinical Trial Summary

Patients with hormone-sensitive prostate cancer and rising PSA, after primary tumor treatment, will be treated with the P501-AS15 vaccine as out-patients. The maximum dose will be 16 vaccinations, given over a period of approximately one year. Thereafter, the patients' long-term safety and PSA status will be followed over a period of approximately 11 months.

Clinical Trial Description

This Phase I/II study will be conducted according to a multicenter, open-label, single-group design at approximately ten centers in Europe. At least 21 HSPC patients with rising PSA after primary tumor treatment will be enrolled in this study. All patients will be treated as out-patients and will receive the same treatment. The maximum dose will be 16 vaccinations. Follow-up: The patients' long-term safety and PSA status will be followed over a period of 48 weeks. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00148928
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date March 1, 2005
Completion date November 7, 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Completed NCT02652000 - Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy N/A
Completed NCT00558363 - ARTS - AVODART After Radical Therapy For Prostate Cancer Study Phase 2
Completed NCT02153918 - Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy Phase 2
Completed NCT01371513 - Korean Practice Patterns for Screening PCA(Prostate Cancer) N/A
Completed NCT00470834 - Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy Phase 4
Completed NCT00056407 - "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Phase 3
Completed NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study Phase 2
Completed NCT00363311 - Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men Phase 4
Completed NCT01337258 - Economic Analyses of the REDUCE Trial N/A
Terminated NCT02349139 - Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer Phase 1
Active, not recruiting NCT04249947 - P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) Phase 1
Completed NCT00883909 - ARI103094-Follow-Up Study for REDUCE Study Subjects N/A